A Case of Multimodality Multiparametric 11C-Choline PET/MR for Biopsy Targeting in Prior Biopsy-Negative Primary Prostate Cancer

Takei, Toshiki MD, PhD*; Souvatzoglou, Michael MD*; Beer, Ambros J. MD*; Drzezga, Alexander MD*; Ziegler, Sybille MD*; Rummeny, Ernst J. MD; Schwaiger, Markus MD*; Eiber, Matthias MD

doi: 10.1097/RLU.0b013e31825b23a6
Interesting Images

Abstract: We introduce the case of a 70-years-old man with an elevated level of prostate-specific antigen and prior negative biopsy. For targeting rebiopsy, the patient underwent 11C-choline PET/CT and subsequent PET/MR. Both the high uptake in PET and the abnormal findings in MR gave strong evidence for prostate cancer at the ventral periphery of the right apex. This location is sometimes not covered by routine sextant biopsy. The following targeted rebiopsy was positive for prostate cancer. This case indicates the potential role of PET/MR for identifying primary prostate cancer because of its high soft tissue contrast and the possibility of a multimodality approach.

From the *Department of Nuclear Medicine and †Institute of Radiology, Klinikum rechts der Isar, Technische Universität München, Munich, Germany.

Received for publication January 24, 2012; revision accepted March 6, 2012.

Conflicts of interest and sources of funding: none declared.

Reprints: Toshiki Takei, MD, PhD, Department of Nuclear Medicine, Klinikum Recht der Isar, Technische Universität München. Ismaninger Str. 22, D-81675, München, Germany. E-mail: toshive@med.hokudai.ac.jp.

Article Outline
Back to Top | Article Outline


1. Beer AJ, Eiber M, Souvatzoglou M, et al.. Radionuclide and hybrid imaging of recurrent prostate cancer. Lancet Oncol. 2011; 12: 181–191.
2. Souvatzoglou M, Weirich G, Schwarzenboeck S, et al.. The sensitivity of [11C]choline PET/CT to localize prostate cancer depends on the tumor configuration. Clin Cancer Res. 2011; 17: 3751–3759.
3. Testa C, Schiavina R, Lodi R, et al.. Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT. Radiology. 2007; 244: 797–806.
4. Fuchsjäger M, Shukla-Dave A, Akin O, et al.. Prostate cancer imaging [review]. Acta Radiol. 2008; 49: 107–120.
5. Haider M, van der Kwast T, Tanguay J, et al.. Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR. 2007; 189: 323–328.
6. Park BK, Lee HM, Kim CK, et al.. Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three tesla before rebiopsy. Invest Radiol. 2008; 43: 789–793.
7. Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol. 2007; 63: 335–350.
8. Scher B, Seitz M, Albinger W, et al.. Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2007; 34: 45–53.

PET/MR; 11C-choline PET; prostate cancer; biopsy

© 2012 Lippincott Williams & Wilkins, Inc.